drugset / Trial / NCT03583021

Sugammadex on Remifentanil Ce for Preventing Emergence Cough in Male

NCT03583021

Completed 42 enrolled Ajou University School of Medicine
RandomizedParallel-groupDouble-blindPrevention

Summary

The primary purpose of this study is to investigate the optimal Ce of remifentanil for preventing emergence cough following extubation during general anesthesia in male patients who are reversed with sugammadex or neostigmine.

Timeline

Start
2018-06-25
Primary completion
2018-10-31
Completion
2018-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Neostigmine Other / unclassified 50 ug/kg Intravenous
Subject Sugammadex Other / unclassified 3 mg/kg Intravenous
Comparator Glycopyrrolate Small molecule 10 ug/kg Intravenous

Indications